Supernus Pharmaceuticals (SUPN) Tops Q3 EPS by 6c

Supernus Pharmaceuticals (NASDAQ: SUPN) reported Q3 EPS of $0.08, $0.06 better than the analyst estimate of $0.02. Revenue for the quarter came in at $38.6 million versus the consensus estimate of $38.1 million.

For earnings history and earnings-related data on Supernus Pharmaceuticals (SUPN) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• IDEX Corp. (IEX) Tops Q1 EPS by 13c ; Offers Guidance
• Baker Hughes Company (BKR) Tops Q1 EPS by 4c, Beats on Revenue